QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
NYSE:NVO

Novo Nordisk A/S (NVO) Stock Forecast, Price & News

$168.55
+1.45 (+0.87%)
(As of 05/18/2023 ET)
Compare
Today's Range
$167.15
$168.69
50-Day Range
$138.89
$172.65
52-Week Range
$95.02
$172.97
Volume
699,679 shs
Average Volume
1.40 million shs
Market Capitalization
$381.42 billion
P/E Ratio
44.36
Dividend Yield
1.00%
Price Target
$383.33

Novo Nordisk A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
127.4% Upside
$383.33 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.63mentions of Novo Nordisk A/S in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.96%
From $4.95 to $5.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

61st out of 989 stocks

Pharmaceutical Preparations Industry

19th out of 477 stocks


NVO stock logo

About Novo Nordisk A/S (NYSE:NVO) Stock

Novo Nordisk A/S is a global healthcare company specializing in the research, development, production, and marketing of pharmaceutical products to treat diabetes, obesity, and other chronic diseases. The company was founded in 1923 in Denmark and is headquartered in Bagsværd, Denmark.

Novo Nordisk has operations in more than 80 countries, including production facilities in nine countries, and employs approximately 48,500 people worldwide.

Novo Nordisk's mission is to discover and develop innovative medicines to help people with chronic diseases lead longer, healthier lives. The company's key therapeutic areas include diabetes, obesity, hemophilia, growth hormone therapy, and other severe chronic diseases. Novo Nordisk is the world's largest producer of insulin and has been at the forefront of diabetes care for more than 95 years.

Lars Fruergaard Jørgensen is the President and CEO of Novo Nordisk A/S, a position he has held since 2017. Jørgensen joined Novo Nordisk in 1991 and has held various management positions, including Executive Vice President and Head of Corporate Development, Strategy and Biopharmaceuticals.

Novo Nordisk has consistently delivered strong financial performance over the past few years. Novo Nordisk's profit margin has remained consistently high, with a net margin of approximately 30%. In terms of debt, Novo Nordisk has maintained a conservative approach. Novo Nordisk's debt has kept pace with its assets for several years. The company's cash reserves have not always been healthy, but in 2022 Novo Nordisk made a profit for the first time since 2018.

Novo Nordisk's valuation metrics compare favorably to industry peers. It has a price-to-earnings ratio in line with its peers but a price-to-book ratio significantly higher than the industry average. Novo Nordisk's high P/B ratio reflects its strong brand, market position, and financial performance.

Novo Nordisk's stock has performed well over the past few years, with a 3-year annualized return of around 23%. The stock price has shown some volatility, with significant price movements in response to regulatory and market news related to diabetes and obesity markets. 

Novo Nordisk operates in the highly competitive and rapidly evolving pharmaceutical industry, specifically in diabetes and obesity markets. The global diabetes market is expected to grow at a CAGR of 5.7% from 2022 to 2027, driven by the increasing prevalence of diabetes, especially in emerging markets, and the growing demand for innovative diabetes treatments. In the obesity market, the global prevalence of obesity has been steadily increasing, and it is expected to continue to rise, driving demand for effective obesity treatments.

Novo Nordisk faces intense competition from several large and small pharmaceutical companies in the diabetes and obesity markets. The company's main competitors in the diabetes market include Sanofi, Eli Lilly, and AstraZeneca, while its main competitors in the obesity market include Roche, Novartis, and Eisai.

The company's competitive position is based on factors such as the quality and effectiveness of its products, its research and development capabilities, its brand reputation, and ability to adapt to changing market dynamics.

Novo Nordisk is also subject to various regulatory and political issues that can impact its operations and financial performance. The company must comply with strict regulatory requirements in each country it operates, including the US FDA and the European Medicines Agency. Changes in regulatory requirements, such as changes to reimbursement policies, can significantly impact the company's financial performance.

Novo Nordisk has several growth opportunities to pursue in the coming years. The company is investing heavily in research and development to develop new and innovative treatments for diabetes and obesity, as well as other chronic diseases. Novo Nordisk has a strong pipeline of potential products in development, including GLP-1 receptor agonists, which have shown promise in clinical trials for treating obesity.

The company also expands in emerging markets, such as China and India, with significant and growing demand for diabetes and obesity treatments. Novo Nordisk has established partnerships with local companies in these markets to help drive growth and increase product access.

Novo Nordisk has pursued acquisitions and partnerships to expand its product offerings and capabilities. In 2021, the company acquired Prothena's ATTR amyloidosis program, a potential treatment for a rare and debilitating disease. This acquisition will strengthen Novo Nordisk's position in the rare disease market.

Novo Nordisk faces several risks and challenges that could impact its operations and financial performance. The company's success is heavily dependent on the success of its products in the diabetes and obesity markets, and any setbacks in clinical trials or product launches could significantly impact its financial performance.

In addition, Novo Nordisk faces regulatory and political risks, as changes in regulations or policies could impact its ability to operate or sell its products in specific markets. The company is also subject to intellectual property risks, as competitors may seek to challenge its patents and market their products.

Novo Nordisk also faces risks related to supply chain disruptions and production delays, as well as cybersecurity and data privacy risks.

Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Stock News Headlines

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market (NVO)
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
The Turnaround for Weight Watchers is Taking Shape (NVO)
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Can Teladoc Stock Be Resuscitated? (NVO)
Virtual healthcare services company Teladoc Health Inc. (NYSE: TDOC) has had a treacherous journey rising to a high of $308 in Feb 2021 and falling to a post-
20 Richest Countries in Europe
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Is Novo Nordisk Stock a Screaming Buy Right Now?
Why Novo Nordisk Stock Is Marching Higher Today
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Company Calendar

Last Earnings
11/02/2021
Ex-Dividend for 4/4 Dividend
3/24/2023
Dividend Payable
4/04/2023
Today
5/18/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
55,185
Year Founded
1923

Price Target and Rating

Average Stock Price Forecast
$383.33
High Stock Price Forecast
$860.00
Low Stock Price Forecast
$145.00
Forecasted Upside/Downside
+127.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$7.86 billion
Pretax Margin
40.34%

Debt

Sales & Book Value

Annual Sales
$25.06 billion
Cash Flow
$3.96 per share
Book Value
$5.09 per share

Miscellaneous

Outstanding Shares
2,262,970,000
Free Float
2,261,385,000
Market Cap
$381.42 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Lars Fruergaard JørgensenLars Fruergaard Jørgensen
    President & Chief Executive Officer
  • Maziar Mike Doustdar
    Executive Vice President-International Operations
  • Karsten Munk KnudsenKarsten Munk Knudsen
    Chief Financial Officer & Executive Vice President
  • Henrik Ehlers Wulff
    Executive VP & Head-Information Technology
  • Stephen Gough
    Global Chief Medical Officer













NVO Stock - Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVO shares.
View NVO analyst ratings
or view top-rated stocks.

What is Novo Nordisk A/S's stock price forecast for 2023?

6 brokerages have issued 12-month price objectives for Novo Nordisk A/S's stock. Their NVO share price forecasts range from $145.00 to $860.00. On average, they expect the company's stock price to reach $383.33 in the next twelve months. This suggests a possible upside of 127.4% from the stock's current price.
View analysts price targets for NVO
or view top-rated stocks among Wall Street analysts.

How have NVO shares performed in 2023?

Novo Nordisk A/S's stock was trading at $135.34 at the beginning of 2023. Since then, NVO shares have increased by 24.5% and is now trading at $168.55.
View the best growth stocks for 2023 here
.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,720,000 shares, a decline of 26.2% from the March 31st total of 2,330,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is presently 1.2 days. Currently, 0.1% of the shares of the stock are sold short.
View Novo Nordisk A/S's Short Interest
.

When is Novo Nordisk A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our NVO earnings forecast
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported $5.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $4.49. The company earned $5.65 billion during the quarter, compared to analyst estimates of $5.64 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 77.39% and a net margin of 32.53%.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Thursday, February 2nd. Stockholders of record on Monday, March 27th will be given a dividend of $1.1887 per share on Tuesday, April 4th. This represents a dividend yield of 0.8%. The ex-dividend date is Friday, March 24th. This is a positive change from the stock's previous semi-annual dividend of $0.58.
Read our dividend analysis for NVO
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $1.69 per share and currently has a dividend yield of 1.01%. The dividend payout ratio is 44.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 29.44% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.09 billion-$31.63 billion, compared to the consensus revenue estimate of $31.90 billion.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (0.55%), Renaissance Technologies LLC (0.48%), Fisher Asset Management LLC (0.35%), Bank of America Corp DE (0.28%), Envestnet Asset Management Inc. (0.23%) and Fayez Sarofim & Co (0.23%).
View institutional ownership trends
.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $168.55.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $381.42 billion and generates $25.06 billion in revenue each year. The company earns $7.86 billion in net income (profit) each year or $3.80 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

The company employs 55,185 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?
The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia Therapeutics, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.

This page (NYSE:NVO) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -